| [1] |
Yonemura Y, Kawamura T, Bandou E, et al. The natural history of free cancer cells in the peritoneal cavity[J]. Recent Results Cancer Res, 2007(169):11-23.
|
| [2] |
Lu Z, Wang J, Wientjes MG, et al. Intraperitoneal therapy for peritoneal cancer[J]. Future Oncol, 2010, 6(10):1625-1641.
|
| [3] |
Garofalo A, Valle M, Garcia J, et al. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites[J]. Eur J Surg Oncol, 2006, 32(6):682-685.
|
| [4] |
Kusamura S, Dominique E, Baratti D, et al. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy[J].J Surg Oncol, 2008, 98(4):247-252.
|
| [5] |
Brigand C, Arvieux C, Gilly FN, et al. Treatment of peritoneal carcinomatosis in gastric cancers[J]. Dig Dis, 2004, 22(4):366-373.
|
| [6] |
Canbay E, Yonemura Y, Brucher B, et al. Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases[J]. Chin J Cancer Res, 2014, 26(1):1-3.
|
| [7] |
Yarema RR, Ohorchak MA, Zubarev GP, et al. Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: results of a single-centre retrospective study[J]. Int J Hyperthermia, 2014, 30(3):159-165.
|
| [8] |
Roviello F, Caruso S, Neri A, et al. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale[J]. Eur J Surg Oncol, 2013, 39(12):1309-1316.
|
| [9] |
Morris DL. Peritonectomy HIPEC-contemporary results, indications[J]. Chin J Cancer Res, 2013, 25(4):373-374.
|
| [10] |
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis[J]. Cancer Treat Res, 1996(82):359-374.
|
| [11] |
Mehta S, Schwarz L, Spiliotis J, et al. Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? results of a multicenter international study[J]. Eur J Surg Oncol, 2018, 44(11):1786-1792.
|
| [12] |
Tabrizian P, Franssen B, Jibara G, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma[J]. J Surg Oncol, 2014, 110(7):786-790.
|
| [13] |
Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer[J]. J Clin Oncol, 2003, 21(20):3737-3743.
|
| [14] |
Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology[J]. Ann Surg Oncol, 2007, 14(1):128-133.
|
| [15] |
Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience[J]. J Clin Oncol, 2009, 27(36):6237-6242.
|
| [16] |
Amblard I, Mercier F, Bartlett DL, et al. Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: a multi-institutional cohort from PSOGI and BIG RENAPE groups[J]. Eur J Surg Oncol, 2018, 44(9):1378-1383.
|
| [17] |
Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study):a propensity score analysis[J]. J Clin Oncol, 2019, 37(23):2028-2040.
|
| [18] |
陈祖龙，吴印兵，唐鸿生，等．腹腔热灌注化疗联合静脉化疗治疗恶性腹水的临床疗效观察[J]．实用医学杂志，2014, 30(18): 2950-2952.
|
| [19] |
王俞，崔书中，巴明臣．腹腔热灌注化疗联合免疫治疗在恶性腹水中的应用[J]．临床肿瘤学杂志，2013, 18(11):1041-1044.
|
| [20] |
Seretis C, Shariff U, Raju T, et al. Proceedings of the 9th international congress on peritoneal surface malignancies, October 9th-11th 2014, Amsterdam[J]. J BUON, 2015, 20(1): 346-347.
|
| [21] |
李雁，周云峰，梁寒，等．细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专家共识[J]．中国肿瘤临床，2015, 42(4):198-206.
|
| [22] |
中国抗癌协会妇科肿瘤专业委员会，中国妇科腹腔热灌注化疗技术临床应用专家协作组．妇科恶性肿瘤腹腔热灌注化疗临床应用专家共识[J]．中国实用妇科与产科杂志，2017, 33(9):926-932.
|
| [23] |
Ellis RJ, Schlick CJR, Yang AD, et al. Utilization and treatment patterns of cytoreduction surgery and intraperitoneal chemotherapy in the United States[J]. Ann Surg Oncol, 2020, 27(1):214-221.
|
| [24] |
Chua TC, Morris DL. Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma[J]. Surg Oncol, 2012, 21(2):95-101.
|
| [25] |
Lin CC, Liang HP, Lee HS, et al. Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis[J]. J Gastroenterol Hepatol, 2009, 24(5):815-820.
|
| [26] |
于建全，冯飞灵，沈洋，等．持续腹腔热灌注化疗治疗进展期胆管癌的临床疗效观察[J]．第二军医大学学报，2017, 38(5):570-575.
|
| [27] |
邹香妮，迟文成，唐寅，等．胆管癌姑息性切除术后持续热灌注化疗用于进展期胆管癌的临床研究[J]．现代消化及介入诊疗，2019, 24(4):382-385.
|
| [28] |
Tentes AA, Stamou K, Pallas N, et al. The effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) as an adjuvant in patients with resectable pancreatic cancer[J]. Int J Hyperthermia, 2016, 32(8):895-899.
|
| [29] |
中国医师协会结直肠肿瘤专业委员会．结直肠癌术中腹腔化疗专家意见(2017版)[J/CD]．中华结直肠疾病电子杂志，2017, 6(6):442-446.
|
| [30] |
张睿，石刚，杨世华，等．洛铂用于结直肠癌术中腹腔灌注化疗的药代动力学研究[J/CD]．中华结直肠疾病电子杂志，2020, 9(2): 144-149.
|
| [31] |
中国医师协会结直肠肿瘤专业委员会腹膜肿瘤专业委员会．结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识（V 2019）[J/CD]．中华结直肠疾病电子杂志，2019, 8(4):329-335.
|
| [32] |
中国抗癌协会腹膜肿瘤专业委员会，广东省抗癌协会肿瘤热疗专业委员会．中国腹腔热灌注化疗技术临床应用专家共识（2019版）[J]．中华医学杂志，2020, 100(2):89-96.
|
| [33] |
腹腔热灌注化疗技术临床应用专家协作组．腹腔热灌注化疗技术临床应用专家共识(2016版)[J]．中华胃肠外科杂志，2016, 19(2):121-125.
|
| [34] |
McKeage MJ. Lobaplatin: a new antitumour platinum drug[J]. Expert Opin Investig Drugs, 2001, 10(1):119-128.
|
| [35] |
Wheate NJ, Walker S, Craig GE, et al. The status of platinum anticancer drugs in the clinic and in clinical trials[J]. Dalton Trans, 2010, 39(35):8113-8127.
|
| [36] |
Peng Y, Liu YE, Ren XC, et al. A phase I clinical trial of dose escalation of lobaplatin in combination with fixed-dose docetaxel for the treatment of human solid tumours that had progressed following chemotherapy[J]. Oncol Lett, 2015, 9(1):67-74.
|
| [37] |
Long GX, Lin JW, Liu DB, et al. Single-arm, multi-centrephase Ⅱ study of lobaplatin combined with docetaxel for recurrent and metastatic nasopharyngeal carcinoma patients[J]. Oral Oncol, 2014, 50(8):717-720.
|
| [38] |
李洋，张明金，赵成功，等．小剂量洛铂术中腹腔灌注对胃肠肿瘤术后复发的影响[J]．现代消化及介入诊疗，2018, 23(4):459-461.
|
| [39] |
Wu HT, Peng KW, Ji ZH, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: results from a Chinese center[J]. Eur J Surg Oncol, 2016, 42(7):1024-1034.
|
| [40] |
Wu Q, Qin SK, Teng FM, et al. Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells[J]. J Hematol Oncol, 2010(3):43.
|
| [41] |
Wang Z, Tang X, Zhang Y, et al. Lobaplatin induces apoptosis and arrests cell cycle progression in human cholangiocarcinoma cell line RBE[J]. Biomed Pharmacother, 2012, 66(3):161-166.
|
| [42] |
韩成龙，马亦龙．洛铂在肝动脉化疗栓塞术中治疗原发性肝癌的近期疗效观察[J]．实用医学杂志，2014, 30(13):2160-2162.
|